Walgreens to sell CBD products in 1,500 stores l GMA



Dr. Jennifer Ashton discusses what to know about CBD products after Walgreens announces they will sell it in creams, patches and sprays at over a thousand …

17 Comments

  1. This is just superb, been searching for "cbd dosage for anxiety mg" for a while now, and I think this has helped. You ever tried – Tenayce Unconventional Transcendence – (Have a quick look on google cant remember the place now ) ? It is a good one of a kind product for discovering how to get rid of pain using CBD cream without the hard work. Ive heard some pretty good things about it and my buddy got excellent results with it.

  2. https://www.ncbi.nlm.nih.gov/pubmed/28588483
    Front Pharmacol. 2017 May 23;8:269. doi: 10.3389/fphar.2017.00269. eCollection 2017
    Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders.  Campos AC1, Fogaça MV1, Scarante FF1, Joca SRL2, Sales AJ2, Gomes FV3, Sonego AB1, Rodrigues NS1, Galve-Roperh I4,5, Guimarães FS1.

    Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia.

    More recently, it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration. These changes and their possible association with CBD beneficial effects in psychiatric disorders are reviewed here.

    https://www.ncbi.nlm.nih.gov/pubmed/28217094

    Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. ECollection 2017            

    In Vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.  Watt G1, Karl T2

    Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do not stop or reverse the disease progression, highlighting the need for new, more effective therapeutics. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties in vitro. Thus, it is investigated as a potential multifunctional treatment option for AD. Here, we summarize the current status quo of in vivo effects of CBD in established pharmacological and transgenic animal models for AD.

    The studies demonstrate the ability of CBD to reduce reactive gliosis and the neuroinflammatory response as well as to promote neurogenesis. Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. Interestingly, combination therapies of CBD and Δ9-tetrahydrocannabinol (THC), the main active ingredient of cannabis sativa, show that CBD can antagonize the psychoactive effects associated with THC and possibly mediate greater therapeutic benefits than either phytocannabinoid alone. The studies provide "proof of principle" that CBD and possibly CBD-THC combinations are valid candidates for novel AD therapies. Further investigations should address the long-term potential of CBD and evaluate mechanisms involved in the therapeutic effects described.

  3. Spoiler alert: BMC Complement Altern Med. 2016 Sep 1;16(1):335. doi: 10.1186/s12906-016-1280-0.
    Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells.
    Lukhele ST1, Motadi LR2.
    Author information
    Abstract
    BACKGROUND:
    Cervical cancer remains a global health related issue among females of Sub-Saharan Africa, with over half a million new cases reported each year. Different therapeutic regimens have been suggested in various regions of Africa, however, over a quarter of a million women die of cervical cancer, annually. This makes it the most lethal cancer amongst black women and calls for urgent therapeutic strategies. In this study we compare the anti-proliferative effects of crude extract of Cannabis sativa and its main compound cannabidiol on different cervical cancer cell lines.

    METHODS:
    To achieve our aim, phytochemical screening, MTT assay, cell growth analysis, flow cytometry, morphology analysis, Western blot, caspase 3/7 assay, and ATP measurement assay were conducted.

    RESULTS:
    Results obtained indicate that both cannabidiol and Cannabis sativa extracts were able to halt cell proliferation in all cell lines at varying concentrations. They further revealed that apoptosis was induced by cannabidiol as shown by increased subG0/G1 and apoptosis through annexin V. Apoptosis was confirmed by overexpression of p53, caspase 3 and bax. Apoptosis induction was further confirmed by morphological changes, an increase in Caspase 3/7 and a decrease in the ATP levels.

    CONCLUSIONS:
    In conclusion, these data suggest that cannabidiol rather than Cannabis sativa crude extracts prevent cell growth and induce cell death in cervical cancer cell lines.

Leave a Reply